Both in Pharmaceuticals
Longeveron vs Aprea Therapeutics
Over the past year LGVN returned −80.3% and APRE returned −66.0%; their daily moves had a correlation of 0.11.
LGVN −80.3% APRE −66.0%Growth of $1, one year, split-adjusted
| Metric | LGVN | APRE |
|---|---|---|
| Price | $1.75 | $0.4936 |
| Market cap | $5.6M | $6.2M |
| Today | −1.69% | −8.22% |
| 1 month | −34.9% | −34.2% |
| 6 months | −79.4% | −38.3% |
| Year to date | −65.4% | −42.1% |
| 1 year | −81.2% | −65.2% |
| Revenue growth (YoY) | −9.2% | −100.0% |
| Gross margin | 63.4% | — |
| Net margin | −2116.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 4.7× | 1,198.6× |
| Net cash | $10.1M | $41.2M |
| Dividend yield | — | — |
| Volatility (60d) | 708.8% | 95.7% |
| Short % of float | 2.8% | 5.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).